Abbott Laboratories Wins FDA Approval for Dual-Energy AFib Catheter

09:04 AM EDT, 09/08/2026 (MT Newswires) -- Abbott Laboratories (ABT) said Tuesday the US Food and Drug Administration approved its TactiFlex Duo ablation catheter to treat patients with challenging cases of atrial fibrillation. The company said the catheter allows physicians to use pulsed field ablation, radiofrequency energy or both during a procedure, giving them more flexibility to target abnormal heart tissue while helping minimize the impact on surrounding areas. The approval was supported by results from Abbott's FlexPulse IDE study, which showed favorable safety and effectiveness outcomes in patients with paroxysmal AFib, the company said. Abbott said it plans to begin broader commercial adoption of the device in the coming weeks.